Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers
Titel:
Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers
Auteur:
Davis, John Hackman, Frances Ndongo, Marie-Noella Choo, HengWee Lewis, Drew Tawadrous, Margaret Goodrich, James Langdon, Grant